借鉴英国制度探讨我国处方药与非处方药“双跨”管理

doi:10.19803/j.1672-8629.2020.12.07

中国药物警戒 ›› 2020, Vol. 17 ›› Issue (12): 883-884.
DOI: 10.19803/j.1672-8629.2020.12.07

借鉴英国制度探讨我国处方药与非处方药“双跨”管理

田春华, 夏东胜

国家药品监督管理局药品评价中心,北京 100022

收稿日期:2020-07-17 修回日期:2020-12-07 出版日期:2020-12-15 发布日期:2020-12-07
作者简介:田春华,女,硕士,副主任药师,药品不良反应监测与评价、非处方药技术评价。

"Double Classification" Management of Prescription Drugs and Non-prescription Drugs in China based on British System

TIAN Chunhua, XIA Dongsheng

Center for Drug Reevaluation,NMPA,Beijing 100022,China

Received:2020-07-17 Revised:2020-12-07 Online:2020-12-15 Published:2020-12-07

摘要/Abstract

摘要： 目的分析英国药品分类管理制度中相同药品不同分类的情况和管理模式,以期为我国处方药与非处方药“双跨”管理提供参考。方法通过对比研究,分析英国和我国处方药与非处方药管理制度、方式的异同。结果和结论 我国处方药与非处方药“双跨”管理符合药品的特性,可借鉴英国分类管理制度和经验完善我国药品分类管理制度。

关键词: 非处方药, "双跨"管理, 英国分类管理制度

Abstract: Objective To analyze the way in which different categories of the same drugs are managed in the drug classification management system in Britain so as to provide reference for the "double classification " management of prescription drugs and non-prescription drugs in China.Methods The similarities and differences in ways of managing prescription drugs and non-prescription drugs between Britain and China were analyzed.Results and Conclusion "Double classification " is consistent with the properties of drugs in China. We can learn from the classification management system and experience of Britain to improve China's drug classification management system.

Key words: non-prescription drugs, "double classification" management, drug classification management system in Britain

中图分类号:

R994.11

田春华, 夏东胜. 借鉴英国制度探讨我国处方药与非处方药“双跨”管理[J]. 中国药物警戒, 2020, 17(12): 883-884.

TIAN Chunhua, XIA Dongsheng. "Double Classification" Management of Prescription Drugs and Non-prescription Drugs in China based on British System[J]. Chinese Journal of Pharmacovigilance, 2020, 17(12): 883-884.

导出引用管理器 EndNote|Ris|BibTeX

链接本文: https://www.zgywjj.com/CN/10.19803/j.1672-8629.2020.12.07

https://www.zgywjj.com/CN/Y2020/V17/I12/883

参考文献

[1] Lan X,Zhen J,Zhai SD.Significance of establishment on the classification management policy of the China prescription medicine and over-the-counter medicine based on foreign experience[J].The Chinese Journal of Clinical Pharmacology(中国临床药理学杂志),2013,29(11):877-880.
[2] Wang LM.The Present and the Future:OTC Drug List in China[J].China Pharmacy(中国药房),2002,13(10):58-60.
[3] National Medical Products Administration.Measures for classified administration of prescription drugs and non-prescription drugs(trial implementation) (Decree No.10 of State Drug Administration) [EB/OL].(1999-06-18)[2020-07-10].http://www.nmpa.gov.cn/WS04/CL2077/300625.html.
[4] National Medical Products Administration.Notice on the Examination and Registration of the Second Batch of Non-prescription Drugs (No.228 of 2002,Department of Drug Regulation) [EB/OL].(2002-07-03)[2020-07-10].http://www.nmpa.gov.cn/WS04/CL2196/323351.html.
[5] National Medical Products Administration.Notice on the conversion of prescription drugs to non-prescription drugs(No.64 of 2010,Department of Drug Registration) [EB/OL].(2010-06-30)[2020-07-10].http://www.nmpa.gov.cn/WS04/CL2196/323778.html.
[6] National Medical Products Administration.Database[EB/OL].[2020-07-10].http://app1.nmpa.gov.cn/datasearchcnda/face3/dir.html.
[7] MHRA.Medicines:reclassify your product [EB/OL].(2019-03-10)[2020-07-10].https://www.gov.uk/guidance/medicines-reclassify-your-product.
[8] Liu JJ,Yang Y.Management of the Prescription and Non-Prescri-ption Drugs Classification in EU[J].Chinese Journal of Pharmacovigilance(中国药物警戒),2014,11(8):472-477.
[9] MHRA.Guidance on how to change the legal classification of a medicine in the UK [EB/OL].(2019-03-10)[2020-07-10].https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/277307/Legal_classification_changes.pdf.

[1]	周玥, 刘硕, 宋海波. 执业药师在药品分类管理中的作用探讨[J]. 中国药物警戒, 2024, 21(4): 428-434.
[2]	许顺贵, 刘春光. 美国非处方药监管制度浅析与启示[J]. 中国药物警戒, 2021, 18(2): 141-144.
[3]	朱兰, 邵波, 夏东胜. 我国遴选与转换中成药非处方药概况及思考[J]. 中国药物警戒, 2020, 17(11): 785-789.
[4]	宋洋, 尤晓敏, 宗毛毛, 杨悦. 我国中药以OTC药品身份在美国上市途径探讨[J]. 中国药物警戒, 2015, 12(9): 547-551.
[5]	王培杰, 王嘉伦, 易智威, 董燕飞, 王璞. 40例喉科非处方中成药不良反应的文献分析[J]. 中国药物警戒, 2015, 12(11): 690-692.
[6]	郑明节, 夏东胜. 非处方药转换申报资料存在的问题分析及建议[J]. 中国药物警戒, 2015, 12(10): 618-622.
[7]	许美婷,薛云丽,杨悦. 美国Rx-OTC转换审评中消费者行为研究对我国的启示[J]. 中国药物警戒, 2015, 12(1): 34-37.
[8]	刘靖杰, 杨悦. 欧盟处方药与非处方药分类管理[J]. 中国药物警戒, 2014, 11(8): 472-477.
[9]	汤韧（译）,范燕（校）. 消费者研究在非处方药中的特殊作用[J]. 中国药物警戒, 2013, 10(7): 447-447.
[10]	汤韧,夏东胜,田春华,王春婷. 我国处方药与非处方药转换的阶段性特点分析[J]. 中国药物警戒, 2013, 10(5): 278-281.
[11]	夏东胜, 田春华,汪鳌,宋秋洁,李岚,杜晓曦. 我国非处方药安全性监测的必要性探讨[J]. 中国药物警戒, 2013, 10(2): 80-83.
[12]	夏东胜,王春婷,刘翠丽,汤韧,范燕,徐帅,田春华. 我国非处方药与不良反应监测的政策对比及启示[J]. 中国药物警戒, 2013, 10(10): 602-606.
[13]	季原, 孙宏峰, 张力. 骨伤科常用非处方口服中成药的安全性评价与合理使用[J]. 中国药物警戒, 2011, 8(6): 352-355.
[14]	夏东胜. 美国青少年非处方药品使用研究简述及对我国的启示[J]. 中国药物警戒, 2011, 8(6): 348-351.
[15]	夏东胜. 非处方药合理使用与不良反应规避策略探讨[J]. 中国药物警戒, 2010, 7(6): 343-346.

借鉴英国制度探讨我国处方药与非处方药“双跨”管理

"Double Classification" Management of Prescription Drugs and Non-prescription Drugs in China based on British System

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics